REGENXBIO Inc. Cash and Cash Equivalents
REGENXBIO Inc. (RGNX) had Cash and Cash Equivalents of $36.49 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $36.49M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $15.23M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $34.47M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $58.80M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $36.49M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $15.23M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $34.47M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $58.80M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $79.56M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $130.10M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $57.53M 10-K · filed 2026-03-05 |
| 2024-09-30 | $56.62M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $57.77M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $112.97M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $34.52M 10-K · filed 2025-03-13 |
| 2023-09-30 | $53.05M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $68.60M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $70.09M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $96.95M 10-K · filed 2025-03-13 |
| 2022-09-30 | $118.54M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $121.37M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $191.87M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $345.21M 10-K · filed 2024-02-27 |
| 2021-09-30 | $228.39M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $257.07M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $291.48M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $338.43M 10-K · filed 2023-02-28 |
| 2020-09-30 | $93.22M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $94.22M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $69.41M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $69.51M 10-K · filed 2022-03-01 |
| 2019-09-30 | $79.59M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $55.14M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $55.85M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $75.56M 10-K · filed 2021-03-01 |
| 2018-09-30 | $142.42M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $106.89M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $71.87M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $46.66M 10-K · filed 2020-02-26 |
| 2017-09-30 | $59.88M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $57.65M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $82.05M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $24.84M 10-K · filed 2019-02-27 |
| 2016-09-30 | $28.11M 10-Q · filed 2017-11-08 |
| 2016-06-30 | $30.08M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $35.51M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $54.12M 10-K · filed 2018-03-06 |
| 2015-09-30 | $205.32M 10-Q · filed 2016-11-09 |
| 2015-06-30 | $85.22M 10-Q · filed 2016-08-09 |
| 2015-03-31 | $25.37M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $1.12M 10-K · filed 2018-03-06 |
| 2014-09-30 | $982.00K 10-Q · filed 2015-11-05 |
| 2013-12-31 | $1.12M 10-K · filed 2017-03-07 |
| 2012-12-31 | $2.17M 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |